Literature DB >> 21587266

Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong.

Satoko Sunagawa1, Jiro Fujita, Futoshi Higa, Masao Tateyama, Shusaku Haranaga, Isamu Nakasone, Nobuhisa Yamane, Tsukasa Uno.   

Abstract

The prevalence of fluoroquinolone-resistant Streptococcus pneumoniae is increasing worldwide. In the present study, a comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin (LVFX)-resistant S. pneumoniae obtained from Hong Kong, Okinawa Island and the Japanese main island (Honshu) was performed. MICs of quinolones (LVFX, tosufloxacin, ciprofloxacin, gatifloxacin and sitafloxacin (STFX)) and other antibiotics (penicillin G, cefcapene, cefditoren, clarithromycin and azithromycin) were determined by a microdilution broth method according to the Clinical and Laboratory Standards Institute Standards. The quinolone-resistance determining regions (QRDRs) of gyrA, gyrB, parC and parE of these strains were analyzed by PCR-based sequencing. All 40 strains tested had more than one amino-acid substitution in the QRDRs of gyrA, gyrB, parC or parE. Although there seemed to be some clonality in strains obtained from Hong Kong, there was no clonality in strains obtained from Okinawa and Japan. Strains obtained from Hong Kong, Okinawa Island and the Japanese main island were genetically different by pulsed-field gel electrophoresis analysis. The range of MIC values of STFX against isolates resistant to LVFX (MIC 4-32 mg l(-1)) was 0.12-0.5 mg l(-1), and MIC(80) values of STFX against LVFX-resistant isolates were 0.25 mg l(-1). This study suggests that LVFX-resistant S. pneumoniae is similar in all three locations and STFX is potent against LVFX-resistant S. pneumoniae with multiple mutations in QRDRs of gyrase A and topoisomerase IV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21587266     DOI: 10.1038/ja.2011.46

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  4 in total

1.  Mechanisms of and risk factors for fluoroquinolone resistance in clinical Enterococcus faecalis isolates from patients with urinary tract infections.

Authors:  Tomihiko Yasufuku; Katsumi Shigemura; Toshiro Shirakawa; Minori Matsumoto; Yuzo Nakano; Kazushi Tanaka; Soichi Arakawa; Masato Kawabata; Masato Fujisawa
Journal:  J Clin Microbiol       Date:  2011-09-14       Impact factor: 5.948

2.  Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model.

Authors:  Wang Liang; Yuan-cheng Chen; Yu-ran Cao; Xiao-fang Liu; Jun Huang; Jia-li Hu; Miao Zhao; Qing-lan Guo; Shu-jing Zhang; Xiao-jie Wu; De-mei Zhu; Ying-yuan Zhang; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

3.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

4.  Development and characterisation of highly antibiotic resistant Bartonella bacilliformis mutants.

Authors:  Cláudia Gomes; Sandra Martínez-Puchol; Lidia Ruiz-Roldán; Maria J Pons; Juana Del Valle Mendoza; Joaquim Ruiz
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.